Pharmaceutical & Biotechnology Middle East (PABME) 2010

More information on Pharmaceutical & Biotechnology Middle East (PABME)

The global pharmaceutical market has demonstrated consistent strong growth
patterns in the past five years generating total revenue of US$ 643 billion in 2006.
Pharmaceutical markets across the world are witnessing increased opportunities
in the area of biopharmaceuticals, pharmacogenomics and biologics.

North America alone accounts for 45% of global pharmaceutical sales with a revenue of $290.1 billion, and the five major European markets (U.K, France, Italy, Germany and Spain) had an estimated revenue of $123.2 billion. Asia Pacific (excluding Japan) and Africa had a revenue of $66 billion while sales in Latin America were $33.6 billion.

And don’t overlook the markets of North Africa, The Levant States and Iran as well
as the newer markets of The GCC countries (Saudi Arabia, Kuwait, Bahrain, Oman,
Qatar and The UAE): combined these markets are valued at over US$12 billion and
are estimated to be growing at an annual rate of over 10%.

With huge investment from both the private and public sector, the Middle East region wants to be not only self sufficient in pharmaceutical production but to also have a large share of the export, research and contract manufacturing side of the industry. Initiatives such as these are being fuelled by the development of governmental ‘free zones’ that can offer generous tax benefits for companies, 100% ownership and a host of other benefits.

Already in the Middle East there estimated to be over 450 pharmaceutical manufacturers – a figure that is growing dramatically year on year. You will be able
to access not only this market but you will also be able to reach all the global manufactures in an unprecedented networking and business opportunity at PABME.